Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc has demonstrated strong financial momentum, with the Integrity product line projecting over 100% revenue growth in 2025 compared to 2024, indicating robust market acceptance and demand. Additionally, the company reported a 41% growth in its regenerative solutions segment, largely attributed to the success of the Integrity patch. Furthermore, international revenue from osteoarthritis pain management increased by 21% year-over-year, reinforcing the company's expanding footprint and sales effectiveness in global markets.

Bears say

Anika Therapeutics experienced a revenue decline of approximately 5.9% to $27.8 million, and an 8.2% decrease to $28.2 million in subsequent periods, indicating ongoing challenges in its top-line growth. Additionally, the company reported a disappointing gross margin of 56%, lower than the estimated 58%, primarily attributed to production yield issues, which further compound its financial difficulties. Furthermore, the international revenue from osteoarthritis pain management dropped by 10% year-over-year, suggesting persistent issues with order timing and production that may hinder future performance.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.